osteoclasts only superficially excavate the surface and fail to generate normal resorptive lacunae (7) .
Despite the critical role played by αvβ3 in skeletal resorption, the molecular mechanisms by which the integrin regulates osteoclast function are incompletely understood. For example, the occupied integrin activates c-src (8, 9) , a molecule central to the osteoclast's capacity to organize its cytoskeleton and resorb bone (10, 11) , but the components of the integrin mediating this event are unknown.
Using a retroviral strategy, we demonstrate full rescue of β3 -/-osteoclast function with a full-length β3 cDNA. This observation permitted us to ask if the β3 cytoplasmic domain, known to transmit intracellular signals in many cell types, is essential for osteoclast function. We find that, in contrast to the complete rescue achieved by full-length β3, deletion of the integrin subunit's cytoplasmic domain renders it completely ineffective in β3 -/-osteoclasts. To identify the components of the β3 cytoplasmic domain regulating osteoclast function, we generated a series of point mutants known, in other circumstances, to mediate β3 integrin signaling. Of the six mutants, only the S 752 P substitution, which also characterizes a form of the human bleeding disorder Glanzmann's thrombasthenia (12) , fails to rescue the spreading and resorptive capacity of β3 -/-osteoclasts or activate c-src upon ligation.
Methods

Retrovirus vector construction.
We used the ∆U3 retroviral vector to express the human β3 integrin (13) . Using human β3 cDNA plasmid as a template, we performed PCR with the following primer pair: 5′-ATCCTCTAGACT-GCCATGCGAGCGCGGCCGCGGCCCCGGCCGCTC-3′ and 5′-CTAGAGATCTTTAAGTGCCCCGGTACGTGATATTGGT-GAAGG-3′. The PCR product was digested with XbaI and BglII and subcloned into the shuttle vector pBluescriptI-ISK (Stratagene, La Jolla, California, USA). The pSK-hβ3 shuttle vector was digested with XbaI and BglII to generate a 2.5-kb insert, which was cloned into the XbaI and BamHI cloning sites of ∆U3 to give rise to ∆U3-hβ3. The vector expressing human β3 lacking the cytoplasmic tail, ∆U3-hβ3∆c, was constructed using the primer pair: 5′-ATCCTCTAGACTGCCATGCGAGCGCGGCCGCGGCCC-CGGCCGCTC-3′ and 5′-CTAGAGATCTTTATTTCCATAT-GAGCAGGGCGGCAAGGCCAATGA-3′.
Mutagenesis.
A 150-bp coding sequence from NdeI to BglII in pSK-hβ3 was used as a mutagenesis cassette. All mutations were generated using the QuickChange Site-directed Mutagenesis Kit (Stratagene). The mutated sites were confirmed by sequencing. The 150-bp fragment containing the desired mutation(s) was then released from the mutagenesis cassette by double digestion with NdeI and BglII, and then used to replace the 150-bp wild-type (WT) sequence of pSK-hβ3. The complete reconstituted full-length β3 cDNA with the desired mutation was subcloned into ∆U3 vector as described above.
Preparation of retrovirus. 293GPG packaging cells were cultured in DMEM with 10% heat-inactivated FBS supplemented with puromycin, G418, and tetracycline as described (13) . ∆U3-hβ3 or its mutants were purified by CsCl gradient centrifugation. ∆U3-hβ3 and ∆U3-hβ3∆c were cotransfected with a plasmid encoding hygromycin into 293GPG cells using LipofectAmine Plus (Life Technologies Inc., Rockville, Maryland, USA). Hygromycinresistant stably transfected clones were selected for 2 weeks in media containing 100 µg/ml Hygromycin B (Sigma Chemical Co., St. Louis, Missouri, USA). The clones producing highest titer of virus, as determined by percent transduction of bone marrow macrophages (BMMs), were expanded, and virus-bearing supernatant was harvested under antibiotic-deficient conditions. Virus from the stable transfectants was used for ∆U3-hβ3 and ∆U3-hβ3∆c. The vectors encoding point mutants were transiently transfected into 293GPG cells using LipofectAmine Plus. Virus was collected at 48-, 72-, and 96-hour time points after transfection.
Infection of the BMMs. Macrophages were isolated from bone marrow of 4-to 8-week-old β3 +/+ or β3 -/-mice, cultured overnight in α-MEM containing 10% heat-inactivated FBS, and subjected to Ficoll-Hypaque (Ficoll; Sigma Chemical Co.; Hypaque 76; Nycomed, Princeton, New Jersey, USA) gradient purification as described (14) . Cells at the gradient interface were collected and cultured in the presence of 10 ng/ml recombinant M-CSF (R&D Systems Inc., Minneapolis, Minnesota, USA) in suspension in Teflon beakers (Fisher Scientific, Pittsburgh, Pennsylvania, USA) for 2 days. Cells were then transduced with virus for 24 hours in the presence of 20 ng/ml recombinant murine M-CSF and 8 µg/ml polybrene (Sigma Chemical Co.), without antibiotic selection. Transduced cells were grown an additional 2-3 days in suspension prior to analysis of expression or osteoclastogenesis.
In vitro generation of osteoclasts. Uninfected or infected marrow macrophages were cultured in α-MEM containing 10% heat-inactivated FBS with ST2 cells in presence of 1 × 10 -8 M 1,25-(OH) 2 vitamin D 3 and 1 × 10 -6 M dexamethasone in 24-well tissue culture plates (1 × 10 5 BMMs and 1 × 10 4 ST2 cells per well). Under these conditions, osteoclasts begin to form at days 6-7. The cultures were stained for tartrate-resistant acid phosphatase (TRAP) activity at days 8-10. Percent area covered by spread osteoclasts was determined using OsteoMeasure software (Osteometrics, Decatur, Georgia, USA).
Bone resorption. Osteoclasts were generated on whale dentin slices from infected or uninfected marrow macrophages as described above. Dentin slices were harvested at days 8-10. Cells were removed from the dentin slices with 0.25 M ammonium hydroxide and mechanical agitation. Dentin slices were then subjected to scanning electron microscopy (15) . Maximum resorption lacunae depth was measured using a confocal microscope (Microradiance; Bio-Rad Laboratories Inc., Hercules, California, USA) as described (7) . For evaluation of pit number and resorbed area, dentin slices were stained with Coomassie brilliant blue and analyzed with light microscopy OsteoMeasure software (Osteometrics).
Immunostaining. In order to avoid background associated with ST2 stromal cells, osteoclasts were generated from transduced and nontransduced precursors on glass coverslips in the presence of 25 ng/ml M-CSF and 40 ng/ml RANKL. After 8-10 days, cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% TritonX-100, rinsed in PBS, and immunostained with 1A2, an mAb against human β3 at 10 µg/ml in 0.1% BSA/PBS (a gift of S. Blystone, Department of Cell and Developmental Biology, State University of New York (SUNY) Upstate Medical University at Syracuse, Syracuse, New York, USA), followed by Cy3-conjugated goat anti-mouse Ab (Chemicon, Temecula, California, USA) and Alexa488-phalloidin (Molecular Probes Inc., Eugene, Oregon, USA).
Flow cytometric analysis. Transduced macrophages were blocked with goat IgG (Sigma Chemical Co.) (50 µg/10 6 cells) for 20 minutes on ice, washed twice with HBSS, and incubated with the anti-β3 mAb 1A2 (10 µg/ml) for 45 minutes on ice. Cells were then rinsed and treated with FITC-conjugated goat-anti-mouse serum (Sigma Chemical Co.) for 30 minutes on ice. As a negative control, we used β3-deficient BMMs infected with ∆U3-nlsβ-gal (which encodes β-galactosidase) and treated as described above. Additionally, negative controls for each cell population were performed by incubating cells with secondary antibody alone. Finally, cells were suspended in 0.5 ml of HBSS and analyzed on a Becton-Dickinson FACScan (Becton-Dickinson Immunocytometry Systems, Mountain View, California, USA).
Src activation. Transduced BMMs were grown in α-MEM with 10% FBS, in the presence of M-CSF and RANKL for 3 days, then starved overnight in medium containing 1% FCS, without cytokines. On the fourth day, cells were lifted with 10 mM EDTA (37°C for 5 minutes) and pipetting, followed by two washes in α-MEM/0.5% BSA. Cells were either maintained in suspension or plated on vitronectin-coated (10 µg/ml, 4°C overnight) plates for 1 hour at 37°C. Suspension cultures or adherent cells were then lysed, as described (9) . Cleared lysates (60 µg/condition) were subjected to immunoprecipitation with PY99-agarose beads (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) at 4°C overnight, followed by immunoblot for p 416 -src (Cell Signaling Technology, Beverly, Massachusetts, USA). As a loading control, 10 µg cleared lysate was analyzed by immunoblot with a monoclonal anti-src antibody (16) .
Results
In vitro, osteoclasts generated from β3 -/-BMMs develop an abnormal cytoskeleton manifested by failure to spread on culture dishes. Furthermore, mutant osteoclasts maintained on whale dentin slices excavate shallow resorption lacunae (7). Thus, we asked if expressing human β3 integrin (hβ3) rescues the abnormal phenotype of β3 -/-murine osteoclasts. We chose the human integrin because (a) high affinity mAb's specific for hβ3 are available, and (b) the cytoplasmic domains of human and murine β3 are identical, making it very likely that hβ3 would be effective in murine cells.
Because authentic osteoclast precursors, namely primary BMMs, are difficult to efficiently transfect, we used a retroviral approach (13) . To this end, we cloned the full-length hβ3 cDNA into the ∆U3 retroviral construct. To determine if integrin-transmitted intracellular signals are essential to osteoclastic bone resorption, we also constructed a retrovirus vector encoding hβ3 lacking its cytoplasmic tail (hβ3∆c) (Figure 1a) .
β3-deficient BMMs were transduced with ∆U3-hβ3 or ∆U3-hβ3∆c, and surface expression of each was analyzed by flow cytometry with an antibody specific for the extracellular domain of hβ3. ∆U3-β-gal served as negative control. Retroviral transduction with either hβ3 construct yields equivalent surface expression of the WT and mutant integrin (Figure 1b) . Following confirmation of hβ3 and hβ3∆c expression, transduced macrophages were cocultured with ST2 stromal cells in osteoclastogenic conditions. Nontransduced WT and β3 -/-BMMs served as controls. Eight days later, the cultures were analyzed for osteoclast expression of the β3 external domain and stained for TRAP activity, a marker of osteoclast differentiation (Figure 2a) . WT cultures consist of very large (150-400 µm diameter), well-spread TRAP-expressing, multinucleated cells. ST2 stromal cells either overlie or are pushed aside by these osteoclasts. β3 -/-cultures also contain numerous TRAP-expressing multinucleated cells, a manifestation of the fact that αvβ3 is not essential for osteoclastogenesis (7) . These osteoclasts, however, spread poorly and therefore appear much smaller. Occasional larger osteoclasts are present but they also fail to spread well or push ST2 cells aside. Expression of full-length hβ3 completely restores the spreading capacity of the mutant osteoclasts. In contrast, expression of the truncated hβ3∆c yields a culture indistinguishable from that containing nontransduced β3 -/-cells. Immunofluorescent staining of mature osteoclasts derived from hβ3-and hβ3∆c-transduced precursors confirms that retroviral-driven expression of these cDNAs persists and localizes with fibrillar actin as BMMs undergo osteoclast differentiation (Figure 2b) .
We next turned to the functional implications of the morphological rescue of β3-deficient osteoclasts. To this end, we generated osteoclasts on whale dentin slices, and after 8 days assessed resorption lacunae formation by scanning electron microscopy. β3 +/+ osteoclasts form well-demarcated deep resorption pits, while those excavated by cells lacking the integrin are substantially fewer in number, shallow, and poorly defined (Figures 2c and 5b) . Reflecting their recovered spreading capacity, the resorptive activity of β3 -/-cells transduced with full-length hβ3 integrin is indistinguishable from their WT counterparts. In contrast, deletion of its intracellular tail abrogates the capacity of the integrin to restore the resorptive activity of β3-deficient cells.
Having established that the cytoplasmic domain of the β3 integrin is essential for osteoclast function, we turned to the individual amino acids mediating this event. On the basis of known regulatory capacity of αv-associated β integrin subunits in other systems (17) (18) (19) (20) (21) (22) , we mutated specific residues in the β3 cytoplasmic domain (Figure 3a) . The mutants were cloned into ∆U3 retroviral construct, which was used to generate retrovirus for transduction of β3 -/-osteoclast precursors.
Once again, osteoclasts generated from uninfected β3 -/-BMMs fail to spread (Figure 3, b and c) . In contrast, infection of β3 -/-osteoclast precursors with hβ3, or any mutant, save one, restores the spreading capacity of their osteoclast progeny, establishing that these altered amino acids are not essential for organization of the osteoclast cytoskeleton. hβ3(S 752 P) is the only mutant which obviates rescue of β3 -/-osteoclasts' capacity to spread. Flow cytometric analysis of transduced BMMs demonstrates that the failure of hβ3(S 752 P) to rescue spreading is not due to diminished surface expression of this mutant in osteoclast precursors (Figure 4a) . Furthermore, immunofluorescent staining of mature osteoclasts demonstrates persistent expression of hβ3(S 752 P) and two other representative mutant β3 cDNAs (Figure 4b ).
Mirroring spreading, the shallow, poorly-defined pits characteristic of β3 -/-osteoclasts are completely normalized by hβ3 and representative, nondisruptive mutants, hβ3(D 723 A) and hβ3(Y 747 F/Y 759 F) (Figure 5a ). The lacunae formed by hβ3(S 752 P), in contrast, appear morphologically similar to those produced by β3 -/-osteoclasts. Quantitative analysis reveals that the number of resorptive pits formed and the percent of dentin surface excavated by β3 -/-osteoclasts transduced with hβ3 or hβ3(D 723 A) are indistinguishable from those generated by WT cells (Figure 5b) . Alternatively, β3 -/-cells bearing hβ3∆c, or the hβ3(S 752 P) mutant, mirror nontransduced β3 -/-osteoclasts for these same indices of resorptive activity. Pit depth is also completely rescued in hβ3 and hβ3(D 723 A) cultures. Interestingly, while hβ3∆c and especially hβ3(S 752 P) transductants generate no more pits than do virgin β3 -/-osteoclasts, they partially normalize pit depth (P < 0.01 compared with both WT and β3 -/-osteoclasts).
We next turned to c-src activation, an intracellular signal mediated by αvβ3, in osteoclasts and asked if the event required the β3 cytoplasmic domain. Early osteoclasts were generated from β3 -/-BMMs transduced with hβ3, hβ3∆c, or the hβ3(S 752 P) and hβ3(Y 747 F/Y 759 F) mutants. The transductants were lifted with EDTA and kept in suspension or plated on the αvβ3 ligand vitronectin. After 1 hour, phosphorylation of c-src at the activation-specific Y 416 site was determined by immunoblot ( Figure 6 ). Adhesion to vitronectin activates c-src in osteoclasts generated from β3 -/-marrow macrophages transduced with intact
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Figure 2
The β3 integrin cytoplasmic domain is essential for osteoclast spreading and resorptive activity. (a) TRAP-stained osteoclast cultures derived from WT and β3 -/-marrow macrophages, and from β3 -/-macrophages transduced with virus encoding hβ3 or hβ3∆c, in coculture with ST2 stromal cells (arrows, osteoclasts; arrowheads, ST2 stromal cells; scale bar = 100 µm). (b) β3 -/-BMMs, either virgin or hβ3-or hβ3∆c-transduced, were cultured in osteoclastogenic conditions for 9 days with M-CSF and RANKL. Cultures were then immunostained with anti-hβ3 external domain mAb and incubated with Alexa488-phalloidin to visualize fibrillar actin. (c) Osteoclasts were generated as in a, on whale dentin. Eight days later, resorption lacunae were examined by scanning electron microscopy. hβ3 or hβ3(Y 747 F/Y 759 F). In contrast, no such activation occurs in osteoclasts bearing hβ3∆c and hβ3(S 752 P), mirroring the functional effects of these mutations.
Discussion
Osteoclastic bone resorption is initiated by matrix recognition, and formation, at the cell-bone interface, of an isolated, acidified microenvironment, which is the site of skeletal degradation (1) . This physical intimacy between the cell and bone indicates that attachment molecules on the osteoclast are pivotal to skeletal remodeling. This posture is buttressed by experiments performed, in vitro and in vivo, demonstrating that αvβ3 blockade blunts the osteoclast's ability to resorb bone (4-6). The clinical relevance of this observation is underscored by the capacity of soluble organic mimetics of the αvβ3 ligand to prevent experimental, postmenopausal osteoporosis (5).
With these experiments in mind, and the wish to determine the role of the αvβ3 integrin in skeletal development, we generated β3-deficient mice (7). Because the platelet integrin αIIbβ3 is not expressed in these animals, they serve as a model of the human bleeding dyscrasia Glanzmann's thrombasthenia (23) . Reflecting osteoclast dysfunction, β3 -/-mice are hypocalcemic and develop bone sclerosis as they age (7) . While the bone phenotype in patients with Glanzmann's thrombasthenia is unknown, a reasonable possibility holds that they too may have increased bone mass. A likely clinical consequence of this phenomenon would be protection against pathological bone loss such as that attending cessation of ovarian function.
The fact that β3 -/-osteoclasts fail to normally organize their cytoskeleton, in vitro and in vivo, represents compelling evidence that the integrin transmits matrixderived signals essential to the resorptive process. Given that the majority of known signaling events mediated by αvβ3 depend upon the β3 cytoplasmic domain, we asked if such was the case regarding the osteoclast. To address this issue, we first expressed full-length hβ3 in β3 -/-osteoclasts. This undertaking was complicated by the fact that primary macrophages, which are osteoclast precursors, cannot be transfected with high efficiency
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The Pit density and resorbed area were determined by examination of Coomassie brilliant blue-stained dentin slices using light microscopy. Pit depth was determined by confocal microscopy. A P < 0.001 compared with WT in all panels; B P < 0.01 compared with both WT and β3 -/-); error bars represent SEM.
Figure 6
Activation of c-src requires the cytoplasmic tail of β3, and is abrogated by the S 752 P mutation but not the Y 747 F/Y 759 F mutation. β3 -/-BMMs transduced with hβ3, hβ3∆c, or the S 752 P and Y 747 F/Y 759 F mutants were grown in M-CSF and RANKL for 3 days to generate early (not fully spread) osteoclasts. Following overnight starvation, cells were lifted with EDTA, and either kept in suspension (S) or adhered to vitronectin-coated plates (A) for 1 hour. As a control, cleared lysates were analyzed by immunoblot for total c-src. Activation of c-src was determined by immunoprecipitation of equal amounts of lysates with the anti-phosphotyrosine Ab PY99, followed by immunoblot with anti-pY 416 src. The ratio of pY 416 src band intensity between adherent and suspension cells (A/S) is indicated, normalized to total c-src levels.
by traditional methods. Thus, we utilized a retroviral strategy (13) which permits effective expression of the transgene in virtually all osteoclast precursors. These transduced cells, when placed in osteoclastogenic conditions, differentiate into osteoclasts indistinguishable from WT, both in their capacity to spread and, most importantly, to resorb bone. In contrast, β3 -/-osteoclasts are unaltered by the β3 integrin transgene lacking the cytoplasmic domain. Thus, signal transduction mediated by the β3 cytoplasmic tail is critical for integrin function in the osteoclast. Previous studies have demonstrated that binding of RGD-containing peptides to the integrin triggers various intracellular signals, including changes in intracellular calcium (24) (25) (26) , and activation of c-src (8), PYK2 (9), p130cas (27) , and PI3-kinase (28) . Despite these observations, the structural components of the β3 cytoplasmic tail mediating osteoclast function have not been elucidated.
In an attempt to identify the amino acid residues in the β3 cytoplasmic tail critical to osteoclastic bone resorption, we generated single and double amino acid mutants based upon the demonstration, in other cells, that they alter β integrin function. D 723 is implicated in forming a salt bridge with the α integrin subunit, thereby stabilizing an activated conformation (20) . P 745 , Y 747 , and Y 759 are located in two NPXY/NXXY motifs which are conserved among most β integrin subunits and mediate many aspects of integrin function (17) (18) (19) . Mutation of integrin β1A-P 781 , which corresponds to β3-P 745 , dampens expression and inactivates β1A in the mouse embryonic stem cell line GD25 (22) .
Of the six point mutants known to impact β integrin function, only S 752 P fails to rescue β3 -/-osteoclasts. This mutation has also been documented in Glanzmann's thrombasthenia (29) , in which platelets fail to aggregate. Thus, the residue regulating human platelet function also regulates the cytoskeletal organization and bone resorptive activity of osteoclasts. Specifically, hβ3(S 752 P) fails to rescue both the impaired capacity of β3 -/-osteoclasts to spread, and the frequency with which they form resorptive lacunae. Similar to platelets (30) , the effect of the mutation is specific for proline, as the more conservative mutation, S 752 A, is as effective as WT hβ3 in rescuing osteoclast spreading (data not shown). This result suggests that local secondary structure, and not phosphorylation of S 752 , likely mediates its central role in osteoclast function.
It is of interest that, like S 752 , Y 747 and Y 759 are, in combination, also essential for platelet function (31) . Both tyrosines, when phosphorylated, bind the signaling molecules SHC and GRB2, as well as the cytoskeletal protein myosin, in platelets (32, 33) . Unlike S 752 , however, these combined mutations fail to impact osteoclast function. Thus, the osteoclast and platelet may share some β3-mediated signaling pathways, while others appear cell-specific.
c-src is a tyrosine kinase essential for osteoclast function (10, 11, 34) . The mechanism by which this protooncogene activates the osteoclast is complex, but clearly involves both the kinase and protein docking domains (35, 36) . We find that αvβ3-dependent activation of c-src requires the cytoplasmic domain of β3, and is abrogated by the S 752 P, but not the Y 747 F/Y 759 F, mutation. Thus, the ability of β3 to activate c-src correlates with its capacity to stimulate osteoclast function.
While the S 752 P mutation affects both osteoclast and platelet function, the downstream signaling mechanisms appear to be distinct. Deletion of c-src has not been reported to cause platelet dysfunction (34) , in contrast to osteoclasts, and therefore is unlikely to represent the relevant β3-mediated signaling pathway in platelets.
Integrin signaling is bidirectional, with inside-out signals affecting ligand binding affinity, and outsidein signals determining intracellular events occurring upon integrin-ligand interaction (37) . In the context of overexpression in Chinese hamster ovary (CHO) cells, Chen et al. (29) showed that the S 752 P mutation disrupts binding of the ligand-induced binding site (LIBS) antibody PAC1, suggesting a defect in insideout signaling. In contrast, we find that σ osteoclasts expressing hβ3(S 752 P) bind AP5, another β3-specific LIBS antibody (R. Faccio, unpublished observations). Given that AP5 recognizes the activated form of αvβ3, this observation suggests that the β3(S 752 P) mutation, in osteoclasts, arrests outside-in signaling and thus, ligand-induced c-src activation.
